Clear and understandable risk communication is essential to informed medical decision making. Our research aims to improve how patients and healthcare providers make pregnancy-related treatment decisions.
>> Learn more about two of our studies: Navigating the Grey Zone and PlGF
Funded by: Canadian Institutes of Health Research (CIHR) and Michael Smith Health Research BC
Read some of our past publications on this topic!
Foggin H, Hutcheon JA, Liauw J. Making sense of harms and benefits: Assessing the numeric presentation of risk information in ACOG obstetrical clinical practice guidelines. Patient Educ Couns. 2021 Aug 28:S0738-3991(21)00576-0. doi: 10.1016/j.pec.2021.08.030
Hutcheon JA, Harper S, Liauw J, Skoll MA, Srour M, Strumpf E. Antenatal corticosteroid administration and kindergarten-age child development: a regression discontinuity study. 2020 PLoS Med 17(12): e1003435
Liauw J, Gundy S, Rochwerg B, Hutcheon JA. Antenatal corticosteroids and COVID-19: balancing benefits and harms. Am J Obstet Gynecol. 2020 Dec;223(6):956-957. doi: 10.1016/j.ajog.2020.08.062.
Liauw J, Burrows J, Crane JM, Lacaze-Masmonteil T, Murphy KE, Boutin A, et al. A Common Language: What Exactly Does 34 Weeks Gestation Mean? J Obstet Gynaecol Can. 2018 Dec;40(12):1623-6.
Skoll A, Boutin A, Bujold E, Burrows J, Crane J, Geary M, Jain V, Lacaze-Masmonteil T, Liauw J, Mundle W, Murphy K, Wong S, Joseph KS. Antenatal Corticosteroid Therapy for Improving Neonatal Outcomes. J Obstet Gynaecol Can 2018;40(9):1219–1239.
Boutin A, Skoll A, Bujold E, Burrows J, Crane J, Geary M, Jain V, Lacaze-Masmonteil T, Liauw J, Mundle W, Murphy K, Wong S, Joseph KS. Antenatal corticosteroid therapy for improving neonatal outcomes: balancing benefits and risks. JOGC 2018. J Obstet Gynaecol Can. 2018;40(9):1193–1197